68-6
73/104

41-8. 13) Horimoto Y, Hlaing MT, Saeki H, Kitano S, Nakai K, Sasaki R, Kurisaki-Arakawa A, Arakawa A, Otsuji N, Matsuoka S, Tokuda E, Arai M, Saito M: Microsatellite instability and mismatch repair protein expressions in lympho-cyte-predominant breast cancer. Cancer Sci, 2020; 111: 2647-54. 14) Watanabe J, Saito M, Horimoto Y, Nakamoto S: A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-admin-istration, in HER2-negative advanced breast cancer patients: A single institutional experi-ence. Breast Cancer Res Treat, 2020; 181: 211-20. 15) Hayward S, Gachehiladze M, Badr N, Andrijes R, Molostvov G, Paniushkina L, Sopikova B, Slobodová Z, Mgebrishvili G, Sharma N, Horimoto Y, Burg D, Robertson G, Hanby A, F Hoar, D Rea, BL Eckhardt, NT Ueno, I Nazarenko, Heather M: Long, Steven van Laere, Abeer M. Shaaban, F Berditchevski: The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer. J Pathol, 2020; 251: 63-73. 16) Nakamuraa M, Ishizuka Y, Horimoto Y, Shiraishi A, Arakawa A, Yanagisawa N, Iijima K, Saito M: Clinicopathological features of breast cancer without mammographic find-ings suggesting malignancy: Breast, 2020; 54: 335-342. 17) Myojin M, Horimoto Y, Ito M, Kitano S, Ishizuka Y, Sasaki R, Uomori T, Himuro T, Murakami F, Nakai N, Iijima K, Saito M: Neutrophil-to-lymphocyte ratio and histolog-ical type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer: Breast Cancer, 2020; 27: 732-738. 18) Shimano H, Miyazaki S, Miura K, Ohtsu H, Yonemoto N, Matsuoka K, Konishi H, Daida H, Saito M, Sase K: Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab: Circ Rep, 2020; 2: 235-242. 19) Yoshida-Ichikawa Y, Horimoto Y, Shikama N, Yanagisawa N, Koyanagi A, Arakawa A, Saito M, Karasawa K: Ipsilateral breast tumor control following hypofractionated and conven-tional fractionated whole-breast irradiation for early breast cancer a long-term follow-up. Breast Cancer, 2020. 20) Furuya H, Hayashi K, Shimizu Y, Kim N, Tsukikawa Y, Chen R, Sun Y, Chan OTM, Pagano I, Peres R, Hokutan K, Igari F, Chan KS, Rosser CJ. J: Plasminogen activator inhibitor-2 (PAI-2) Overexpression supports in PAI- bladder cancer development 1knockout mice in N-Butyl-N-(4-hydroxy-butyl)-nitrosamine-induced bladder cancer mouse model. Transl Med, 2020; 18: 57. 21) Komoda M, Yamaguchi S, Takahashi K, Yanase K, Umezawa M, Miyajima A, Yoshi-masu T, Sato E, Ozeki R, Ishii N: Efficacy and safety of a combination regimen of pheno-thrin and ivermectin lotion in patients with head lice in Okinawa, Japan. J Dermatol, 2020; 47: 720-727. 22) Higashi N, Irimura T, Nakajima M: Hepara-nase is Involved in Leukocyte Migration. Adv Exp Med Biol, 2020; 1221: 435-444. 23) Kaoru N, Hiroshi K, Akiko C, Mizuho K, Masami A, Daisuke I, Shoichi S, Shoichi Y, Yusuke H, Akiyoshi I, Toshiyuki Y, Toshiaki H, Tomohiro T, Junko F: Phenotypic varia-tions of gastric neoplasms in familial adeno-matous polyposis are associated with the endoscopic status of atrophic gastritis. Dig Endosc, 2020; 64: 547-556. 24) Masuzawa K, Asakura T, Ikemura S, Yasuda H, Kawada I, Takaoka S, Hayashi Y, Nakajima T, Arai M, Fukunaga K, Soejima K: Long-Lasting Response to Nivolumab for a Patient With Lynch Syndrome-Associated Lung Adenocarcinoma. JCO Precis Oncol, 2020; 4: 74-78. 25) Arai M: Recent Advances in the Treatment of Hereditary Breast and Ovarian Cancer in Japan -Elucidation of Clinical and Patholog-ical Characteristics, Establishment of a Nation- wide Registration System, and Improvement of Clinical Practice. Juntendo Med J, 2020; 66: 384-391. 26) Okano M, Nomizu T, Tachibana K, Nagat-suka M, Matsuzaki M, Katagata N, Ohtake T, Yokoyama S, Arai M, Nakamura S: The rela-637

元のページ  ../index.html#73

このブックを見る